We are a COVID-19 Testing Facility

Have you or a loved one been diagnosed with the KRAS G12C mutation - Non-Small Cell Lung Cancer?

A clinical study for adults diagnosed with Non-Small Cell Lung Cancer with the KRAS G12C mutation

Why is the RMC-4630 study being done?

The purpose of this study is to test a new drug called RMC-4630 in combination with Sotorasib. RMC-4630 is a new investigational (experimental) drug, which means that it is not yet approved by the US Food and Drug Administration (FDA) or any other health authorities. Sotorasib (LUMAKRAS™) has been approved by the FDA for participants with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). This study will test the safety and anti-tumor effects of RMC-4630 and Sotorasib when given together in patients with KRAS G12C-mutated locally advanced or metastatic NSCLC.

Who can participate in the RMC-4630 study?

You may be eligible to participate in this study if you:

What happens during the study?

There are 3 study periods: screening, treatment, and follow-up. All aspects of your participation will take place at the study location or at your place of residence. 

Screening:

Treatment:

Follow-Up:

What treatment will I receive?

You will receive both RMC-4630 and Sotorasib.

What tests will I have?

During the study, you may have tests to assess:

What else will I have to do?

Follow the study staff’s directions regarding the study.

Will I receive compensation for participating in this study?

Yes, you will receive $333 upon your completion of the screening visit and $183 for each subsequent clinical visit. Additionally, you will be compensated for $50 for each follow-up call that occurs every 3 months until your withdrawal or termination from the study.







GenHarp Clinical Solutions

9730 S. Western Ave., Suite 218 Evergreen Park, IL 60805
872-205-3149